Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Ovarian cancer treatment has advanced due to better understanding of its biology.
• Homologous recombination (HR) deficiency is linked to improved responses to chemotherapy and PARP inhibitors.
• Tumor immunogenicity varies by ovarian cancer histotype.

Purpose of the Study:

• To review the interplay between the immune system, DNA repair, and intraperitoneal therapies in ovarian cancer.
• To explore potential future therapeutic strategies based on current biological and clinical data.

Main Methods:

• Literature review of biological and clinical data.
• Analysis of the relationship between DNA repair defects, immune response, and treatment outcomes.
• Focus on intraperitoneal therapies and their immune-modulating potential.

Main Results:

• HR deficiency correlates with increased tumor-infiltrating lymphocytes, suggesting combination therapy potential.
• Locoregional therapies, like heat shock and chemotherapy, can stimulate an anticancer immune response.
• There is a significant interplay between immune system, DNA repair mechanisms, and intraperitoneal treatments in ovarian cancer.

Conclusions:

• Ovarian cancer treatment can be enhanced by targeting DNA repair defects and leveraging the immune system.
• Combination therapies involving PARP inhibitors and immune-modulating agents warrant further investigation.
• Locoregional approaches hold potential for impacting the immune system in ovarian cancer treatment.